INSIGHTS ON PHARMACEUTICAL PACKAGING
-
![West-SOP 2 - GCApp_LCMSQof]( "Key Considerations When Developing Your Combination Product")
Key Considerations When Developing Your Combination ProductSucceed in combination product development by understanding the risk factors that may arise and implementing mitigation strategies that will streamline the device development process.
-
![West-PO 3 - GCApp]( "Meeting Annex 1: A Proactive Approach To Regulatory Compliance")
Meeting Annex 1: A Proactive Approach To Regulatory ComplianceIt was imperative for a large European CMO producing multiple biologics to select the right product quality and value for each customer to comply with the August 2023 EU GMP Annex 1 revision.
-
![GettyImages-1087219526-scientist-computer-screen-compliance-sterilization]( "New Standards For Elastomeric Components In Sterile Packaging")
New Standards For Elastomeric Components In Sterile PackagingUSP’s new elastomeric packaging standards shift testing to full system‑level evaluation, strengthen integrity and usability expectations, and place compliance responsibility on drug developers.
-
![BO 2 - GC_App_^CZ vial with stopper and seal stack up]( "Bringing A Biosimilar For Oncology To Market: Injectable Packaging From Early Development To Commercialization")
Bringing A Biosimilar For Oncology To Market: Injectable Packaging From Early Development To CommercializationWhile in their early-stage development of a mAb biosimilar for oncology treatment, a large biopharmaceuticals company sought a packaging recommendation: a stopper to maintain high-quality standards.
-
De-Risking The Transition From Vial To Drug-Device Combination Product7/25/2025
When transitioning from a vial to a combination product system, the best approach is to have a holistic de-risk strategy with an intentional focus on the patient, the plan, and the product.
-
Integration Of Container Closure Integrity In Contract Manufacturing3/28/2025
Maintaining drug product sterility and compliance demands rigorous Container Closure Integrity (CCI) within contract manufacturing. Learn how to fortify your processes.
-
PCI Pharma Services Capabilities Update January 2026: Fill/Finish2/4/2026
Patricia highlights PCI’s global sterile fill‑finish and lyophilization strengths, showcasing investments that expand capacity, technologies, and integrated solutions for complex biologics, formulations, and lyophilized products.
-
3D Screen Printing: Enabling A New Generation Of Complex Formulations3/17/2025
Screen-Printed Innovative Drug Technology can produce oral, transdermal, and implantable dosage forms while ensuring heterogeneous distribution of active ingredients.
-
Selecting Container Closure Systems With Confidence: Lyophilization3/7/2024
Experts take you through the entire selection process for primary packaging components for lyophilization and provide aspects to consider for all relevant attributes.
PHARMACEUTICAL PACKAGING SOLUTIONS
-
![GettyImages-2086161977-blister-packaging-liquid-medical-medicine]( "Your Full-Service Supplier")
For clinical trial packaging services, beyond transparency and flexibility, you need absolute reliability.
-
![IMA Precisa 18 High Speed Tablet Capsule Checkweigher]( "Used Pharmaceutical Tablet And Capsule Checkweigher From IMA: Precisa 18")
IMA Precisa 18 High Speed Tablet/Capsule Checkweigher, serial# PA1114.
-
Our global capabilities span a scale of commercial packaging requirements from targeted therapies for select populations including biologics, through to large-scale projects requiring sophisticated technology integration. With true customer focus and flexibility at our core, we are able to adapt to the unique requirements of each global market need including brand and generic ethical pharmaceuticals, biotech medicines, over-the-counter pharmaceuticals, consumer healthcare products, specialized requirements for medical devices and specialty products.
-
![Syringe-Staked-In-Needle-iStock-502347386 (002)]( "Pharmaceutical Package Integrity Testing")
The pharmaceutical industry continues to bring breakthroughs in the field of new drugs and drug delivery systems amidst the increased scrutiny of the regulators. The packaging acts as the primary sterile barrier in drug delivery systems that safeguard the drug product through its life cycle. The efficiency of the primary sterile barrier and the functional components are of utmost importance to patient safety.
-
![X34C xray inspection]( "X-Ray Inspection System For High Level Contamination Detection")
Compact, High-Speed and Precise
A unique solution which inspects individually wrapped food or pharmaceutical products at high line speeds. The X34C combines a short total footprint with an optimized focal distance to enhance detection of non-conforming products and reducing waste
